A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Phase 4

Recruiting

• Conditions: Facial Contouring
• Interventions: Drug: OnabotulinumtoxinA; Device: JUVÉDERM; Device: CoolSculpting Elite System; Other: SkinMedica Products; Drug: KYBELLA

• Registration Number: NCT06783621
• Lead Sponsor: AbbVie

Brief Summary

A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-01-15
• Study First Submitted QC: 2025-01-15
• Study Start: 2025-01-16
• Study First Posted: 2025-01-20
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-07
• Last Update Posted: 2025-04-09
• Primary Completion: 2026-07
• Study Completion: 2026-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Applies to All Participants:

• Must meet at least 1 of the following criteria for BOTOX UFL treatment per investigator's assessment:

  • Moderate or severe on Allergan Glabellar Line Severity Scale at maximum furrow
  • Moderate or severe on Forehead Line Severity Scale at maximum brow elevation and Moderate or Severe on Allergan Glabellar Line Severity Scale at maximum furrow
  • Moderate or severe on Lateral Canthal Line Severity Scale at maximum contraction (identical severity on both sides)

• Must meet at least 3 of the following criteria for treatment in the face with at least 2 JUVÉDERM products, per investigator's assessment:

  • Moderate or severe on Allergan Loss of Jawline Definition Scale
  • Moderate or severe on Allergan Chin Retrusion Scale
  • Moderate, significant, or severe on Midface Volume Deficit Scale
  • Moderate or severe on Nasolabial Fold Severity Scale
  • Moderate or severe for both eyes on Allergan Infraorbital Hollows Scale
  • Minimal, mild, or moderate on 5-point Allergan Lip Fullness Scale
  • Moderate or severe on Allergan Cheek Smoothness Scale
  • Minimal, moderate, or severe on Allergan Temple Hollowing Scale

Applies only to participants who will be treated with submental fat:

• Moderate or severe on the Clinician-reported Submental Fat Rating Scale (for KYBELLA treatment) or Moderate, severe, or extreme (For CoolSculpting Elite treatment) per investigator's assessment.

Exclusion Criteria

• History of medical condition that may put the subject at increased medical risk with exposure to OnabotulinumtoxinA, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
• History of hypersensitivity or allergy to any botulinum toxin serotype, Streptococcal protein, lidocaine (or any amide-based anesthetics), HA products, any other excipients or constituents of the study drug, device, SkinMedica products and/or other products in the same class.
• Marked facial asymmetry (e.g., asymmetry in eyebrow and/or eyelid position, asymmetrical smile or significant asymmetry in the lower face), facial nerve palsy, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart.
• Previous plastic surgery, tissue grafting, permanent facial implants (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene), or tissue augmentation with silicone, fat, or other permanent dermal fillers of the face and/or neck or plan to undergo any of these procedures at any time during the study.
• Prior exposure to botulinum toxin of any serotype to any part of the body within 6 months prior to screening.
• Prior treatment with non-permanent soft tissue fillers or fat-reducing injectables in the face or neck within 12 months prior to screening.
• Prior treatment with energy-based devices (e.g., intense pulsed light, Clear + Brilliant®, monopolar radiofrequency, microfocused ultrasound, etc.,) or other noninvasive fat reduction procedure and/or skin-tightening laser treatments in the face or neck within 6 months prior to screening.
• Current use or planned treatment with weight loss medications during the study (including but not limited to glucagon-like peptide-1 agonists, or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonists).
• History of body weight change of > 10% over the 6 months prior to screening, or anticipated body weight change of > 10% during the study period.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open-Label Combination Treatments	OnabotulinumtoxinA	All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).
Open-Label Combination Treatments	JUVÉDERM	All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).
Open-Label Combination Treatments	CoolSculpting Elite System	All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).
Open-Label Combination Treatments	SkinMedica Products	All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).
Open-Label Combination Treatments	KYBELLA	All participants in the study will receive treatment with onabotulinumtoxinA and JUVÉDERM (specific products and indications will be at the discretion of the investigator and per participant eligibility criteria).

Primary Outcome Measures

Name	Time	Method
Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Satisfaction with Facial Appearance Scale at the Final Visit	Up to approximately 284 days	The FACE-Q Satisfaction with Facial Appearance is a validated questionnaire that asks participants to report their level of satisfaction with the appearance of their face.

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Psychological Function Scale at the Final Visit	Up to approximately 284 days	The FACE-Q Psychological Function is a validated questionnaire that asks participants to report their level of satisfaction with psychological function.
Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Social Function Scale at the Final Visit	Up to approximately 284 days	The FACE-Q Social Function Scale is a validated questionnaire that asks participants to report their level of satisfaction with social function.
Change from Baseline in the Participant's Rasch-Transformed Score of the SKIN-Q Scale at the Final Visit	Up to approximately 284 days	The SKIN-Q Scale is a validated questionnaire that asks participants to report their level of satisfaction with skin quality.

Trial Locations

Locations (10)

Center for Dermatology and Dermatologic Surgery /ID# 270390; 🇺🇸 Washington, District of Columbia, United States

Marcus Facial Plastic Surgery /ID# 270408; 🇺🇸 Redondo Beach, California, United States

Pacific Clinical Innovations /ID# 270414; 🇺🇸 Vista, California, United States

Skin Research Institute LLC /ID# 270410; 🇺🇸 Coral Gables, Florida, United States

DelRicht Research - New Orleans 308 /ID# 270425; 🇺🇸 New Orleans, Louisiana, United States

Boyd /Id# 270509; 🇺🇸 Birmingham, Michigan, United States

Luxurgery /ID# 270430; 🇺🇸 New York, New York, United States

Bellaire Dermatology Associates /ID# 270429; 🇺🇸 Bellaire, Texas, United States

Integrated Aesthetics /ID# 270399; 🇺🇸 Spring, Texas, United States

SkinDC /ID# 270411; 🇺🇸 Arlington, Virginia, United States